ConductScience.org, home

Paper36453028

Preclinical evaluation of CDK4 phosphorylation predicts high sensitivity of pleural mesotheliomas to CDK4/6 inhibition.

Paternot S and 17 others. Mol Oncol, 2024. Cited by 7 papers, by iCite.

Cite this record

ConductScience Library. Preclinical evaluation of CDK4 phosphorylation predicts high sensitivity of pleural mesotheliomas to CDK4/6 inhibition. Papers, record 36453028. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/36453028

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Preclinical evaluation of CDK4 phosphorylation predicts high sensitivity of pleural mesotheliomas to CDK4/6 inhibition.
PubMed
Journal
Mol Oncol
PubMed
Year
2024
PubMed
Publication types
Journal Article, Research Support, Non-U.S. Gov't
PubMed
Citations, by iCite
7
iCite
Relative citation ratio, by iCite
0.85, provisional
iCite
Revised in PubMed
2026-08-28
PubMed

Authors18

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Paternot SSabinehttps://orcid.org/0000-0002-3028-8223
2Raspé EEric
3Meiller CClément
4Tarabichi MMaxime
5Assié JBJean-Baptiste
6Libert FFrederick
7Remmelink MMyriam
8Bisteau XXavier
9Pauwels PPatrick
10Blum YYuna
11Le Stang NNolwenn
12Tabone-Eglinger SSéverine
13Galateau-Sallé FFrançoise
14Blanquart CChristophehttps://orcid.org/0000-0002-0917-3747
15Van Meerbeeck JPJan P
16Berghmans TThierry
17Jean DDidierhttps://orcid.org/0000-0001-5823-7404
18Roger PPPierre P

Source PubMed

Download CSV of authors

Topics8

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Mesothelioma, MalignantMajor topic
MesotheliomaMajor topic
Pleural NeoplasmsMajor topic
Humans
Phosphorylation
Cell Proliferation
Cell Line, Tumor
Cyclin-Dependent Kinase 4

Source PubMed

Download CSV of topics

Grants21

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated by
Academic Medical Interdisciplinary Research (AMIR) Foundation (ASBL)PubMed
ARSMESO44PubMed
Belgian National Cancer PlanPubMed
Cancéropôle Ile-de-FrancePubMed
Chancellerie des Universités de ParisPubMed
Fondation pour la Recherche MédicalePubMed
J.0002.16Fonds De La Recherche Scientifique - FNRSPubMed
J.0141.19Fonds De La Recherche Scientifique - FNRSPubMed
J.0169.22Fonds De La Recherche Scientifique - FNRSPubMed
7.4589.17Fonds De La Recherche Scientifique - FNRSPubMed
H2020 Marie Skłodowska-Curie ActionsPubMed
InnovirisPubMed
Institut National de la Santé et de la Recherche MédicalePubMed
Institut National Du CancerPubMed
Koning BoudewijnstichtingPubMed
Ligue Contre le CancerPubMed
National Health InstitutePubMed
2014-130Stichting Tegen KankerPubMed
2018-138Stichting Tegen KankerPubMed
1710166WALInnovPubMed

Source PubMed

See all 21 grantsDownload CSV of grants

References133

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
18939678The retinoblastoma protein pathway and the restriction point.Curr Opin Cell Biol1996https://conductscience.org/library/papers/8939678PubMed
222291433Cyclin-dependent kinase inhibitor 1B (CDKN1B) gene variants in AIP mutation-negative familial isolated pituitary adenoma kindreds.Endocr Relat Cancer2012https://conductscience.org/library/papers/22291433PubMed
39447971Functional inactivation of the retinoblastoma protein requires sequential modification by at least two distinct cyclin-cdk complexes.Mol Cell Biol1998https://conductscience.org/library/papers/9447971PubMed
434568836Distinct CDK6 complexes determine tumor cell response to CDK4/6 inhibitors and degraders.Nat Cancer2021https://conductscience.org/library/papers/34568836PubMed
520609353A synthetic lethal interaction between K-Ras oncogenes and Cdk4 unveils a therapeutic strategy for non-small cell lung carcinoma.Cancer Cell2010https://conductscience.org/library/papers/20609353PubMed
616782892Regulated activating Thr172 phosphorylation of cyclin-dependent kinase 4(CDK4): its relationship with cyclins and CDK "inhibitors".Mol Cell Biol2006https://conductscience.org/library/papers/16782892PubMed
733941591Inhibition of CDK4/6 Promotes CD8 T-cell Memory Formation.Cancer Discov2021https://conductscience.org/library/papers/33941591PubMed
819237555The structure of CDK4/cyclin D3 has implications for models of CDK activation.Proc Natl Acad Sci U S A2009https://conductscience.org/library/papers/19237555PubMed
933485464First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial.Lancet2021https://conductscience.org/library/papers/33485464PubMed
1016413469Requirement for CDK4 kinase function in breast cancer.Cancer Cell2006https://conductscience.org/library/papers/16413469PubMed
1134544752INK4 Tumor Suppressor Proteins Mediate Resistance to CDK4/6 Kinase Inhibitors.Cancer Discov2022https://conductscience.org/library/papers/34544752PubMed
1234592265Inhibition of Cyclin Dependent Kinase 4/6 Overcomes Primary Resistance to Programmed Cell Death 1 Blockade in Malignant Mesothelioma.Ann Thorac Surg2022https://conductscience.org/library/papers/34592265PubMed
1330065701Landscape of CDKN1B Mutations in Luminal Breast Cancer and Other Hormone-Driven Human Tumors.Front Endocrinol (Lausanne)2018https://conductscience.org/library/papers/30065701PubMed
1426719230Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial.Lancet2016https://conductscience.org/library/papers/26719230PubMed
1534930610Chemotherapy With or Without Bevacizumab Should Be the Standard of Care for First-Line Unresectable Epithelioid Mesothelioma.J Thorac Oncol2022https://conductscience.org/library/papers/34930610PubMed
1631745297Chemotherapy impacts on the cellular response to CDK4/6 inhibition: distinct mechanisms of interaction and efficacy in models of pancreatic cancer.Oncogene2020https://conductscience.org/library/papers/31745297PubMed
1729590617Regulation of Cellular Senescence by Polycomb Chromatin Modifiers through Distinct DNA Damage- and Histone Methylation-Dependent Pathways.Cell Rep2018https://conductscience.org/library/papers/29590617PubMed
1831174843Cell Cycle and Beyond: Exploiting New RB1 Controlled Mechanisms for Cancer Therapy.Trends Cancer2019https://conductscience.org/library/papers/31174843PubMed
1928003305Co-occurring Mutations of Tumor Suppressor Genes, LATS2 and NF2, in Malignant Pleural Mesothelioma.Clin Cancer Res2017https://conductscience.org/library/papers/28003305PubMed
2032233024Galacto-conjugation of Navitoclax as an efficient strategy to increase senolytic specificity and reduce platelet toxicity.Aging Cell2020https://conductscience.org/library/papers/32233024PubMed

See all 133 referencesDownload CSV of references

Cited by8

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 7 citations.

PMIDTitleJournalYearIn PapersSource
42842196Manganese-Enhanced Magnetic Resonance Imaging: From Translational Research to First-in-Human Trials in Oncology.Mol Diagn Ther2026https://conductscience.org/library/papers/42842196PubMed
42215475CDK4/6 inhibition uncovers subtype-specific vulnerabilities and immune-related responses in esophageal squamous cell carcinoma.Cell Death Dis2026https://conductscience.org/library/papers/42215475PubMed
41963314Pseudo-senescence induced by palbociclib does not sensitise pleural mesothelioma cells to combinations with senolytics.Cell Death Dis2026https://conductscience.org/library/papers/41963314PubMed
40904706Pleural Mesothelioma: Pathogenesis, Diagnosis, Treatment, Prognosis, and Survival.MedComm (2020)2025https://conductscience.org/library/papers/40904706PubMed
39011477Pharmacological inhibition of CDK4/6 impairs diffuse pleural mesothelioma 3D spheroid growth and reduces viability of cisplatin-resistant cells.Front Oncol2024https://conductscience.org/library/papers/39011477PubMed
37964967CDK4 phosphorylation status and rational use for combining CDK4/6 and BRAF/MEK inhibition in advanced thyroid carcinomas.Front Endocrinol (Lausanne)2023https://conductscience.org/library/papers/37964967PubMed
37266562CDK4/6 inhibition confers protection of normal gut epithelia against gemcitabine and the active metabolite of irinotecan.Cell Cycle2023https://conductscience.org/library/papers/37266562PubMed
36765923CDK4/6 Inhibitors in Pancreatobiliary Cancers: Opportunities and Challenges.Cancers (Basel)2023https://conductscience.org/library/papers/36765923PubMed

Download CSV of cited by

Genes5

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
CCNE1898PubTator's text mininghttps://conductscience.org/library/genes/898NCBI Gene
CDK41019PubTator's text mininghttps://conductscience.org/library/genes/1019NCBI Gene
CDK61021PubTator's text mininghttps://conductscience.org/library/genes/1021NCBI Gene
CDKN2A1029PubTator's text mininghttps://conductscience.org/library/genes/1029NCBI Gene
RB15925PubTator's text mininghttps://conductscience.org/library/genes/5925NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Trials
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/36453028

GET https://conductscience.org/api/papers/v1/36453028/grants?page=2